Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576103 · ClinicalTrials.gov registry record
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
A clinical trial of Glioma and Meningioma, sponsored by Jona Hattangadi-Gluth.
- Recruiting
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT05576103: Recruiting study of Glioma and Meningioma, sponsored by Jona Hattangadi-Gluth.
NCT05576103 is a study of Glioma and Meningioma that is actively recruiting participants, run by Jona Hattangadi-Gluth. The registered enrollment target is 250 participants, above the 207-participant average among 87 other Glioma trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05576103, a study of Glioma and Meningioma, is actively recruiting participants, sponsored by Jona Hattangadi-Gluth.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.
Primary Outcome
To measure longitudinal changes in volume (cc) from volumetric MR imaging
Conditions Studied
Study Locations (1)
California
- Moores Cancer Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-01 |
| Est. Completion | 2026-12 |
What NCT05576103 shows while recruiting
NCT05576103 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 207-participant average among 87 other Glioma trials with a reported enrollment target (21% higher).
The record links to 4 conditions, with Glioma appearing as the primary indexed condition, and to 0 interventions.
NCT05576103 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05576103 about?
NCT05576103 is a clinical study titled "Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients". In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through...
What is the current status of trial NCT05576103?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2015-01. Estimated completion is 2026-12.
What conditions does trial NCT05576103 study?
This clinical trial studies the following conditions: Glioma, Meningioma, Primary Brain Tumor, Schwannoma.
Who is sponsoring clinical trial NCT05576103?
This trial is sponsored by Jona Hattangadi-Gluth, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05576103 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05576103's enrollment target sits among peer trials
250 6th of 87 higher than 82 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia